Klinisch-neuroleptische Untersuchung des N-[(l-Äthyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulfamoyl- Benzamid-Neuroleptikums Sulpirid (Dogmatil®) an akut erkrankten Schizophrenen

Abstract

The paper reports on 26 acute, first time or repeatedly diseased schizophrenic patients, who were treated by Sulpiride in a psychiatric ward. The method used was a variant of the single-blind technique of administration and evaluation, the basic conception being that of the ‘neuroleptic threshold’ of Haase. The substance proved to be an intermediary drug between feeble and middle-potent neuroleptics. In doses about 200 mg/ day, it showed a mood-clearing and stimulating effect. The average dosis necessary to reach the neuroleptic threshold was 399 mg Sulpiride, the average time being 6 days. An average dosis of 593.3 mg daily produced in an average time of 11.5 days, dependent from the initial dose, an evident antipsychotic effect. A good indication for Sulpiride therapy seemed to be the inhibited and withdrawn patients, but also the restless, highly productive psychoses, of which 17 from 23 cases showed good results. Extrapyramidal side effects were not important and could easily be kept under control. Only a certain drowsiness after very high doses was registered. The indication of Sulpiride in the ambulatory treatment and in post-psychotic depressions are discussed.

Repeated Phencyclidine Treatment Induces Negative Symptom-like Behavior in Forced Swimming Test in Mice Imbalance of Prefrontal Serotonergic and Dopaminergic Functions

“…Thus, our PCP model could be used as a new model of the negative symptoms. Haase et al (1974) reported that chronic schizophrenic patients given sulpiride, a selective dopamine 2 receptor antagonist, showed an elation of mood and clearing of negative signs. Elizur and Davidson (1975) also found sulpiride is effective in improving the autistic state of schizophrenic patients.…”

Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system

“…The antipsychotic action of these agents, however, is possibly not connected with the impairment of the nigrostriatal dopamine transmission. In fact, sulpiride (Borenstein, Champion & others, 1969;Haase, Florn & Ulrich, 1974;Tagliamonte, de Montis & others, 1975), clozapine (Burki, Eichenberger & others, 1975) and thioridazine (Cole & Clyde, 1961), which are claimed to display antipyschotic properties (1) do not cause marked extrapyramidal side effects in either man or animals and (2) are by far less potent than classical neuroleptic drugs (e.g. chlorpromazine and haloperidol) in enhancing striatal dopamine turnover which is thought to be triggered by the blockade of dopamine receptors (vide infra).…”

Clinical Evaluation of Sulpiride in Schizophrenic Patients ‐ A Double‐blind Comparison with Chlorpromazine

“…However, in a previous study we found 800 mg of sulpiride to be effective in the treatment of psychotic patients (20). Moreover, Haase et al (12) found an antipsychotic effect with 600 mg of sulpiride. Chlorpromazine was selected as reference.…”

“…This in turn may indicate a lower risk of inducing tardive dyskinesia. The drug has also been claimed to be especially effective in autistic patients (12,13,10). Several double-blind comparisons with conventional neuroleptics like chlorpromazine, haloperidol and trifluoperazine indicate that sulpiride has antipsychotic effect in schizophrenic patients (14,15,16,17,18,19).…”